We are career venture capitalists, biotech founders, former pharma and biotech executives, research scientists, medical doctors, and experienced drug developers. What unites us is the passion for biotech start-ups, innovation and the quest for new and better medicines.
Managing Partner at BB Biotech Ventures since 2004. Co-founder and, from 2008 till 2016, Executive Chairman of Vaximm. Prior to joining Bellevue, Investment Manager at GLS Ventures in Munich. He has invested in a number of bio-pharmaceutical companies, such as Glycart, Intercell, Pevion, Vaximm and AM-Pharma. PhD Molecular Biologist & Chemist.
Former Founder & CEO of ESBATech, a Swiss biotech focusing on next generation antibody drugs. Alcon acquired ESBATech for USD 589 million in 2009. Subsequently until 2016 Vice President of Alcon R&D. Member of the Global Ophthalmology Leadership and Global Biologics Leadership. Since 2002, on the Board of the Swiss Biotech Association and President since 2013. PhD Molecular Biologist.
Managing Partner at BB Biotech Ventures since 2004. Prior to joining Bellevue Group, Investment Manager at BioMed, HBM and NMT. Martin’s past and current board assignments include Bellevue’s most successful private biopharmaceutical investments, such as Radius Health, Molecular Partners, Optimer Pharmaceuticals, Axovan and Glycart. PhD Protein Chemist & Biochemist.
Former EVP, COO and board director of Cellectis, a premier CAR T-cell and DNA editing company, NASDAQ listed (CLLS). Prior to that, Head of Global Pharmaceutical Operations at Pierre Fabre and in senior corporate and regional roles at Wyeth (US and Europe). Medical Doctor.